Maze Q4 net loss $34.6M; MZE829 Phase 2 35.6% uACR drop; Neil Kumar joins board

Maze Therapeutics, Inc.

Net loss $34.6M in Q4, $131.1M for FY2025; cash $360M provides runway into 2028.
MZE829 Phase 2 HORIZON: mean uACR reduction 35.6% at week 12; 50% patients >30% reduction.
FSGS subgroup 61.8% mean uACR reduction; non-diabetic AMKD 48.6%; well-tolerated, no serious AEs.
Neil Kumar (BridgeBio CEO) appointed to board effective March 27, 2026; receives option grant.
Plans to advance MZE829 to pivotal program; MZE782 Phase 2 trials in PKU and CKD expected in 2026.

item 2.02 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Maze Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

Period: the fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 25, 2026, Maze Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the fourth quarter and year ended December 31, 2025.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Maze Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-122774

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.